259 related articles for article (PubMed ID: 8221672)
21. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis.
Määttä M; Soini Y; Liakka A; Autio-Harmainen H
Clin Cancer Res; 2000 Jul; 6(7):2726-34. PubMed ID: 10914717
[TBL] [Abstract][Full Text] [Related]
22. [Significance of activated matrix metalloproteinase 2 (MMP2) in progression of bladder transitional cell carcinoma].
Zhang XP; Zhou FJ; Shen PF; Zhou C; Wei JX
Ai Zheng; 2003 Jun; 22(6):637-9. PubMed ID: 12948424
[TBL] [Abstract][Full Text] [Related]
23. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas.
Forsyth PA; Wong H; Laing TD; Rewcastle NB; Morris DG; Muzik H; Leco KJ; Johnston RN; Brasher PM; Sutherland G; Edwards DR
Br J Cancer; 1999 Apr; 79(11-12):1828-35. PubMed ID: 10206300
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential.
Arii S; Mise M; Harada T; Furutani M; Ishigami S; Niwano M; Mizumoto M; Fukumoto M; Imamura M
Hepatology; 1996 Aug; 24(2):316-22. PubMed ID: 8690399
[TBL] [Abstract][Full Text] [Related]
25. Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade.
Bianco FJ; Gervasi DC; Tiguert R; Grignon DJ; Pontes JE; Crissman JD; Fridman R; Wood DP
Clin Cancer Res; 1998 Dec; 4(12):3011-6. PubMed ID: 9865914
[TBL] [Abstract][Full Text] [Related]
26. Urinary gelatinase activities (matrix metalloproteinases 2 and 9) in human bladder tumors.
Di Carlo A; Terracciano D; Mariano A; Macchia V
Oncol Rep; 2006 May; 15(5):1321-6. PubMed ID: 16596205
[TBL] [Abstract][Full Text] [Related]
27. Membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation in primary human ovarian epithelial carcinoma cells.
Fishman DA; Bafetti LM; Stack MS
Invasion Metastasis; 1996; 16(3):150-9. PubMed ID: 9186550
[TBL] [Abstract][Full Text] [Related]
28. Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro.
Yamamoto M; Mohanam S; Sawaya R; Fuller GN; Seiki M; Sato H; Gokaslan ZL; Liotta LA; Nicolson GL; Rao JS
Cancer Res; 1996 Jan; 56(2):384-92. PubMed ID: 8542596
[TBL] [Abstract][Full Text] [Related]
29. Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers.
Sier CF; Casetta G; Verheijen JH; Tizzani A; Agape V; Kos J; Blasi F; Hanemaaijer R
Clin Cancer Res; 2000 Jun; 6(6):2333-40. PubMed ID: 10873084
[TBL] [Abstract][Full Text] [Related]
30. Urinary type IV collagenase: elevated levels are associated with bladder transitional cell carcinoma.
Margulies IM; Höyhtyä M; Evans C; Stracke ML; Liotta LA; Stetler-Stevenson WG
Cancer Epidemiol Biomarkers Prev; 1992; 1(6):467-74. PubMed ID: 1302559
[TBL] [Abstract][Full Text] [Related]
31. Implication of collagen type I-induced membrane-type 1-matrix metalloproteinase expression and matrix metalloproteinase-2 activation in the metastatic progression of breast carcinoma.
Gilles C; Polette M; Seiki M; Birembaut P; Thompson EW
Lab Invest; 1997 May; 76(5):651-60. PubMed ID: 9166284
[TBL] [Abstract][Full Text] [Related]
32. Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer.
Durkan GC; Nutt JE; Marsh C; Rajjayabun PH; Robinson MC; Neal DE; Lunec J; Mellon JK
Clin Cancer Res; 2003 Jul; 9(7):2576-82. PubMed ID: 12855633
[TBL] [Abstract][Full Text] [Related]
33. Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma.
Kugler A; Hemmerlein B; Thelen P; Kallerhoff M; Radzun HJ; Ringert RH
J Urol; 1998 Nov; 160(5):1914-8. PubMed ID: 9783985
[TBL] [Abstract][Full Text] [Related]
34. Tumor cell invasion through matrigel is regulated by activated matrix metalloproteinase-2.
Deryugina EI; Luo GX; Reisfeld RA; Bourdon MA; Strongin A
Anticancer Res; 1997; 17(5A):3201-10. PubMed ID: 9413149
[TBL] [Abstract][Full Text] [Related]
35. Expression of metalloproteinase-2, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in transitional cell carcinoma of upper urinary tract: correlation with tumor stage and survival.
Miyata Y; Kanda S; Nomata K; Hayashida Y; Kanetake H
Urology; 2004 Mar; 63(3):602-8. PubMed ID: 15028476
[TBL] [Abstract][Full Text] [Related]
36. Expression of matrix metalloproteinase-1, -2 and -3 in squamous cell carcinoma and actinic keratosis.
Tsukifuji R; Tagawa K; Hatamochi A; Shinkai H
Br J Cancer; 1999 Jun; 80(7):1087-91. PubMed ID: 10362121
[TBL] [Abstract][Full Text] [Related]
37. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients.
Iizasa T; Fujisawa T; Suzuki M; Motohashi S; Yasufuku K; Yasukawa T; Baba M; Shiba M
Clin Cancer Res; 1999 Jan; 5(1):149-53. PubMed ID: 9918213
[TBL] [Abstract][Full Text] [Related]
38. [Expressions of MMP-2 and COX-2 mRNA in bladder transitional cell carcinoma and their correlation].
Zhang HP; Yu B; Zheng XD; Hu HJ; Gao ZB; Li L; Zhou LF
Zhonghua Nan Ke Xue; 2008 Nov; 14(11):1011-4. PubMed ID: 19102503
[TBL] [Abstract][Full Text] [Related]
39. Transcriptional suppression of matrix metalloproteinase-2 gene expression in human astroglioma cells by TNF-alpha and IFN-gamma.
Qin H; Moellinger JD; Wells A; Windsor LJ; Sun Y; Benveniste EN
J Immunol; 1998 Dec; 161(12):6664-73. PubMed ID: 9862695
[TBL] [Abstract][Full Text] [Related]
40. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer.
Murray GI; Duncan ME; O'Neil P; McKay JA; Melvin WT; Fothergill JE
J Pathol; 1998 Jul; 185(3):256-61. PubMed ID: 9771478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
